Data sources. With computerized databases and references from published articles, prospective trials that compared ThinPrep and conventional smears were identified. The computerized databases consisted of MEDLINE, PubMed (National Library of Medicine, Bethesda, Md), and Silver Platter (Silver Platter Information Inc, Norwood, Mass). The searches were conducted for literature published in English between January 1990 and April 2000. Medical subject heading key words included "ThinPrep," "liquid-based cytology," and "Pap smear."
Methods of study selection. Criteria for selection of these studies included prospective trials that evaluated diagnostic cytology according to the Bethesda system nomenclature, as well as adequacy of ThinPrep test compared with that of the conventional smear. Clearly documented data from split-sample and direct-to-vial (casecohort) studies were assessed. The split-sample method involved obtaining a Papanicolaou smear in a routine fashion, swabbing the glass slide, and then rinsing the residual material into a liquid preservative (PreservCyt, Cleveland, Ohio). The split-sample method was deemed an acceptable means of evaluation, because studies have shown that up to 80% of cells may remain on the sampling device after preparation of the conventional smear. Direct-to-vial studies involved the collection of conventional Papanicolaou smears and ThinPrep specimens separately from the same population base. Publications were evaluated for quality of method, inclusion and exclusion criteria, description of sampling protocols, definition of reported outcomes, and statistical analyses. The search yielded 24 published articles 1, and one abstract 25 that met inclusion criteria for this metaanalysis.
Forty-nine publications of liquid-based thin-layer cytotechnology were identified (references available on request). Twenty-four were excluded on the basis of use of different thin-layer technology, lack of comparison to conventional smears, and lack of evaluation of specific outcome measures. Twenty-five publications were identified that met inclusion criteria for this review. Eighteen trials were performed in the United States, * one in Canada, 11 one in Japan, 3 two in Australia, 14, 16 one in Costa Rica, 2 one in Taiwan, 17 and one in Switzerland. 24 A total of 533,039 women were enrolled in these trials-221,864 in the ThinPrep group and 378,659 in the conventional smear group. A total of 67,484 women were involved in split-sample trials and thus were included in both ThinPrep and conventional smear groups. * References 1,4-10,12,13,15,18-23, and 25.
Tabulation and integration. Split-sample and direct-tovial studies were analyzed separately. Both versions of the ThinPrep processor (Beta and ThinPrep 2000) were incorporated and evaluated together, as well as independently. All direct-to-vial studies and 6 of 17 split-sample studies used ThinPrep 2000, whereas the remaining 11 of 17 split-sample trials were performed with the ThinPrep Beta model. Outcomes examined included the following: (1) frequency of diagnoses of atypical cells of undetermined significance, low-grade squamous intraepithelial lesions, and high-grade squamous intraepithelial lesions; and (2) adequacy of sample collection for appropriate evaluation. An adequate smear is defined as one that contains squamous cells, endocervical cells, and possibly metaplastic cells representative of the transformation zone. Unsatisfactory smears or inadequate samples are those described in the studies as limited by components such as poor fixation, scant squamous epithelial component, thick smear, obscuring blood or inflammation, absent endocervical component, or cytolysis. 17 Because of the small number of atypical glandular cells of undetermined significance diagnoses in various trials, 12, 13, 18, 19, 25 some studies included in this metaanalysis combined atypical squamous cells of undetermined significance and atypical glandular cells of undetermined significance into the same category. For the purpose of this metaanalysis, atypical squamous cells of undetermined significance and atypical glandular cells of undetermined significance were also combined into one category-atypical cells of undetermined significance. Only three 18, 19, 25 of eight direct-to-vial and two 12, 13 of the 14 split-sample studies evaluated atypical glandular cells of undetermined significance and atypical squamous cells of undetermined significance independently. The remaining studies were unable to perform a reasonable analysis because of the small number of atypical glandular cells of undetermined significance smears. Although we acknowledge that atypical glandular cells of undetermined significance and atypical squamous cells of undetermined significance are two distinct categories in the Bethesda system, we were unable to analyze them as such in this study, and the inability to separate these data is one of the weaknesses of a metaanalysis.
Statistical analysis. Analysis of the data was performed with the Stata 5.0 (College Station, Tex) statistical software package. The odds ratios (OR) for each outcome and 95% confidence intervals (CI) were calculated in the ThinPrep group and compared with the conventional smear group. Estimates of ORs and risk differences for dichotomous outcomes were calculated by use of random-effects (DerSirmonian and Laird) and fixedeffects (Mantel-Haenszel) models. The differences between results with either method were not substantial, therefore only fixed-effects results are reported. A test of heterogeneity was performed to evaluate the ability to combine the individual trials (as described by Breslow and Day 26 ). Ta bles X, XI, and XII). As made evident in these tables, the fact that the case-cohort trials used direct rinsing of cervical cells into the liquid medium (rather than secondary placement as seen in split-sample trials) made a significant difference in the percent of specimens considered adequate for evaluation.
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Numerous publications have reported mixed viewpoints regarding the effectiveness of the ThinPrep test in replacing the conventional smear for routine uterine cervical cancer screening. This metaanalysis reveals that ThinPrep appears to be a superior method of evaluating uterine cervix cytologic abnormalities with regard to lowgrade and high-grade lesions, as well as a better means of obtaining specimen adequacy for improved evaluation. Our data show that ThinPrep did not reduce the rate of atypical cells of undetermined significance diagnosis.
Neither ThinPrep nor the conventional Papanicolaou test was favored when evaluating atypical squamous lesions, and in part this may be due to lack of division of atypical cells of undetermined significance into atypical glandular and atypical squamous cells of undetermined significance in all of the studies. When analyses specifically separating atypical glandular cells from atypical squamous cells of undetermined significance were evaluated, the number of studies available for atypical glandular cells of undetermined significance evaluation was too small to enable formation of a significant conclusion. Three 18, 19, 25 of the eight direct-to-vial and two 12, 13 of the 14 split-sample studies analyzing atypical cells of undetermined significance separated atypical glandular cells from atypical squamous cells of undetermined significance. For this reason, atypical glandular cells and atypical squamous cells of undetermined significance were combined in all studies included in this systematic review to obtain the power necessary to reach a reasonable conclusion.
Several tables indicate a high heterogeneity when analyzing pooled data. This in part may be due to combining trials evaluating low-risk and high-risk populations, because this can have a significant effect on diagnosis on the basis of the relative incidence of disease. As noted in Tables II, III One of the significant problems with conventional smears is screening error. Limited transfer of cells from the collecting device to the slide of a conventional smear, as well as faulty interpretation of these smears contributes to a significant number of screening errors. ThinPrep not only improves the amount of cells transferred for evaluation but also presents cells on slides in an automated fashion in a manner that is easier for the cytotechnologist to interpret.
To evaluate cervical cytologic study results in a timely and efficient manner, sufficient specimen adequacy is required. The differences in evaluation of specimen adequacy may be due to several factors, including variation in sampling devices, sampling techniques, and the use of split-sample specimens. Also not all studies included in this metaanalysis evaluated sample adequacy, thus limiting the overall sample power. The trials included in this study used various types of sampling devices, including broom-type, plastic spatula with or without an endocervical brush, modified wooden Ayer's spatula with or without an endocervical brush, cytobrush, CervexBrush (Rovers Medical Devices, BV, Oss, the Netherlands), Cervibrush Profile Plus (CellPath, West Yorkshire, United Kingdom), and Accellon Combi (Medesign, Dietramszeu-Linden, Germany) cervical biosampler. This varia- August 2001 Am J Obstet Gynecol tion in devices may contribute to differences in results in the individual trials, because some collection apparatuses may function better than others. A discussion regarding different devices is out of the scope of this analysis. For the purpose of this study, the assumption was made that a good cross-section of tools and techniques was used, thus simulating conventional smear collection worldwide. Split-sample studies may have created a bias against ThinPrep because of a potential lack of transfer of enough cells necessary to make a proper diagnosis, albeit not affecting the overall outcome of this metaanalysis.
Although direct-to-vial studies are unable to directly compare samples from the same patient, they do indicate a statistically significant improvement in the detection of endocervical cells. Linder and Zahniser 1 have demonstrated that ThinPrep reduces the number of samples that are satisfactory but limited by blood, mucus, poor fixation, and inflammatory processes. The improved sample adequacy seen in this metaanalysis is likely the result of its ability to remove blood, debris, and mucus, improve fixation and preservation of cell structure, and ensure uniform sampling, thus likely decreasing the need for repeat Papanicolaou smears because of these factors. To pursue the incidence of false-positive diagnoses and sensitivity issues, further testing with histologic comparisons should be performed. Currently there are few histologic comparisons that are similar enough to evaluate as a metaanalysis.
Concerns regarding the increase in cost for ThinPrep processing compared with conventional smears are valid. A cost analysis reviewed by Sedlacek and Cooper 27 indicates an overall saving in lifetime costs for the diagnosis and treatment of uterine cervix abnormalities with the use of ThinPrep versus the conventional smear. The decrease in overall cost was attributed to reduced number of office visits, as well as fewer treatment and follow-up visits. From our data, this decrease in cost does not appear to be derived from re- Bernstein, Sanchez-Ramos, and Ndubisi 315
Am J Obstet Gynecol duced diagnoses of atypical cells of undetermined significance but perhaps from improved sampling adequacy. Although these results are encouraging for ThinPrep, more studies need to be performed pertaining to this topic.
The results of this systematic review indicate that ThinPrep is superior to the conventional smear when evaluating most of the outcome variables in this study. Further studies analyzing the histologic correlation of these findings need to be performed to evaluate more definitively the sensitivity and specificity of ThinPrep as a more accurate screening method.
Discussion
DR BARBARA MOORE, Roanoke, Va. This article makes a significant contribution to the field of gynecology by assessing a possible improvement in the conventional Papanicolaou smear, one of the most effective screening tests in medicine. Why does a test that has reduced the incidence of invasive cervical cancer by 70% need improvement? The answer lies in the highly variable sensitivity of the conventional Papanicolaou smear, with multiple studies indicating a high number of false-negative results that are primarily due to sampling error.
ThinPrep technology was initially approved by the Food and Drug Administration in 1991 for nongynecologic indications, and its usefulness had been demonstrated in smear preparation of urine and bronchial cytologic study, as well as fine needle aspirations. In 1996 the Cytyc Corporation received approval to use ThinPrep for cervical cytologic study, and many important advantages over the conventional Papanicolaou smear have been proposed: (1) decreased frequency of atypical squamous and atypical glandular cells of undetermined significance; (2) decreased patient anxiety over diagnoses of atypical squamous or glandular cells of undetermined significance; (3) increased detection of low-and high-grade squamous intraepithelial lesions; (4) decreased inadequate smears because of the filtering out of blood, mucus, and inflammatory cells; (5) decreased overall costs through fewer repeat Papanicolaou smears for inadequate samples, less colposcopy for atypical squamous cells of undetermined significance, and more efficient reading of slides by cytotechnologists; and (6) availability August 2001 Am J Obstet Gynecol of human papilloma virus typing, gonorrhea, and chlamydia testing on the original sample without an additional patient visit and examination. Rigorous scientific assessment of these claims is essential to avoid enthusiastic, well-intentioned universal adoption of a new technology with great promise in much the same way that fetal monitoring was embraced.
Dr Bernstein clearly states the purpose of this study was the evaluation of cytologic diagnoses and sample adequacy of ThinPrep smears compared with conventional Papanicolaou smears. The design of the study is sound. Twentyfive prospective studies with clear outcome data comparing the two smear results were selected for the metaanalysis from a collection of 49 studies published in a 10-year period from 1990 to 2000. Those selected represent 7 countries and both low-and high-risk populations. The total sample size is more than 500,000 women, whereas the original data presented by the manufacturer for Food and Drug Administration approval included only 7300 subjects.
The choice of statistical tests was appropriate, with odds ratios used with a 95% confidence interval. Random-effects and fixed-effects models were compared, and a test of heterogeneity was performed to determine whether such varying studies could be analyzed together. Because of differences in ThinPrep collection, the directto-vial studies, in which the specimen is placed directly into the liquid medium, were analyzed separately from split-sample studies, in which the cells remaining on the collection device after preparation of the conventional Papanicolaou smear are then placed in the ThinPrep vial.
The statistical results of the metaanalysis support the following results stated in Dr Bernstein's article: (1) Sample adequacy was significantly improved by ThinPrep. (2) ThinPrep did not significantly decrease the number of diagnoses of atypical cells of undetermined significance, as shown by a confidence interval that included 1.00. (3) ThinPrep produced significantly more diagnoses of lowgrade squamous intraepithelial lesions. (4) ThinPrep produced significantly more diagnoses of high-grade squamous intraepithelial lesions in the direct-to-vial studies. However, analysis of the split-sample studies does not show this because of a confidence interval that includes 1.00. Thus Dr Bernstein's metaanalysis supports ThinPrep's improved sample adequacy and the increased diagnosis of squamous intraepithelial lesions.
In deciding whether to adopt the ThinPrep smear as an alternative to or replacement for the conventional Papanicolaou smear, it is helpful to review the criteria for a good screening test: high patient acceptability as a result of minimal discomfort, detection of a treatable condition, accuracy, and low cost. ThinPrep and conventional Papanicolaou smears do not differ on these first two criteria. Is the accuracy of ThinPrep equal to or greater than that of conventional Papanicolaou smear? The comparison of cervical cytologic study with histologic study from colposcopic biopsy specimens and endocervical curettage would seem to be the most helpful in determining accuracy.
Finally, the cost-effectiveness of ThinPrep must be evaluated before it can be widely adopted as a superior screening test. More than 50 million Papanicolaou smears are performed annually in the United States alone, with an 8% rate of abnormal findings. This represents a cost of almost $6 billion to detect and treat squamous intraepithelial lesions. 1 Is ThinPrep's increased cost offset by fewer inadequate smears, fewer readings of atypical squamous and glandular cells of undetermined significance, more accurate detection of low-and high-grade squamous intraepithelial lesions allowing earlier treatment, and more efficient cytotechnologist reading? As Dr Bernstein noted, Sedlacek and Cooper's study has shown an overall lifetime cost savings. Clearly, though, additional studies are needed to show whether acceptable cost-effectiveness would be realized with ThinPrep.
What is your rationale for stating that ThinPrep increases the detection of high-grade squamous intraepithelial lesions in split-sample studies when the 95% confidence interval includes 1.00? How many studies in your metaanalysis included histologic correlation with colposcopic biopsy and endocervical curettage? Would a separate analysis of these studies be helpful? With what patient population do you believe ThinPrep technology should be used, in those with prior low-or high-grade squamous intraepithelial lesions, or should it be universally applied?
